Is CSL the best blue-chip share on the S&P/ ASX200?

An Australian share market success story.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite the CSL Limited (ASX: CSL) share price being down 17% from its all-time highs, it still remains one of Australia's greatest ASX success stories.

Headquartered in Melbourne, CSL has become a global biotech company by focussing on "saving lives and protecting the health of people who were stricken with a range of serious and chronic medical conditions". This focus has led the company's share price to grow at an annualised rate of 19.3% over the last decade, excluding its growing dividend.

The company has a number of products on the market, however its core product is its blood plasma collection business. Analysts believe that this business can grow by high single digits for the foreseeable future. Because of this robust growth the company is aiming to open between 30 to 35 new collection centres this financial year.

CSL currently has five new products moving into human clinical trials. The company has a strong history of investing in research and development (R&D), in order to generate a diverse and growing revenue base. At 31 December 2018, CSL spent 8.7% of total operating revenue on R&D.

A financial key

One of the keys to CSL's share price success is the exceptional 42% return-on-equity (RoE) that it generates. This is possible because the company has used debt to leverage its assets. Without this debt the RoE would be a more moderate 16%.

By historical measures the cost of borrowing has been extremely low for a number of years now. This has enabled companies like CSL to use debt to fund some of their growth. One benefit that CSL has over other companies is that its products are less cyclical and it has strong cash flows. This enables the company to service its interest payments.

For FY19 CSL is targeting the upper end of its full year profit guidance. This would represent 13% year on year growth to between US$1,880 million and US$1,950 million. Shares currently trade around 32x estimated forward earnings and offer an unfranked dividend yield of 1%.

Foolish bottom line

Although CSL trades on a rich valuation compared to its current earnings growth, the strong track record and long term prospects of the company are sound. I'd like to buy shares cheaper than they are today, however it is important to note that high quality companies like CSL generally trade at a premium.

If you like the sound of CSL, here are some other high quality growth companies.

Lloyd Prout has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »